

The Etiologies, Pathophysiology, and Alternative/Complementary Treatment of Asthma

Alan L. Miller, ND

Abstract

A chronic inflammatory disorder of the respiratory airways, asthma is characterized by bronchial airway inflammation resulting in increased mucus production and airway hyper-responsiveness. The resultant symptomatology includes episodes of wheezing, coughing, and shortness of breath. Asthma is a multifactorial disease process with genetic, allergic, environmental, infectious, emotional, and nutritional components. The underlying pathophysiology of asthma is airway inflammation. The underlying process driving and maintaining the asthmatic inflammatory process appears to be an abnormal or inadequately regulated CD4⁺ T-cell immune response. The T-helper 2 (Th2) subset produces cytokines including interleukin-4 (IL-4), IL-5, IL-6, IL-9, IL-10, and IL-13, which stimulate the growth, differentiation, and recruitment of mast cells, basophils, eosinophils, and B-cells, all of which are involved in humoral immunity, inflammation, and the allergic response. In asthma, this arm of the immune response is overactive, while Th1 activity, generally corresponding more to cell-mediated immunity, is dampened. It is not yet known why asthmatics have this out-of-balance immune activity, but genetics, viruses, fungi, heavy metals, nutrition, and pollution all can be contributors. A plant lipid preparation containing sterols and sterolins has been shown to dampen Th2 activity. Antioxidant nutrients, especially vitamins C and E, selenium, and zinc appear to be necessary in asthma treatment. Vitamins B6 and B12 also may be helpful. Omega-3 fatty acids from fish, the flavonoid quercetin, and botanicals *Tylophora asthmatica*, *Boswellia serrata*, and *Petasites hybridus* address the inflammatory component. Physical modalities, including yoga, massage, biofeedback, acupuncture, and chiropractic can also be of help.

Altern Med Rev 2001;6(1):20-47.

Introduction

Asthma is a chronic inflammatory disorder of the respiratory airways, characterized by increased mucus production and airway hyper-responsiveness resulting in decreased air flow, and marked by recurrent episodes of wheezing, coughing, and shortness of breath. It is a multifactorial disease process associated with genetic, allergic, environmental, infectious, emotional, and nutritional components. Because of their symptomatology the majority of individuals with asthma experience a significant number of missed work or school days. This can create a severe

Alan L. Miller, ND – Technical Advisor, Thorne Research, Inc.; Senior Editor, *Alternative Medicine Review*.
Correspondence address: PO Box 25, Dover, ID 83825. E-mail: alan@thorne.com

disruption in quality of life, often leading to depressive episodes. It also disrupts the lives of caregivers and family members of the affected individual. Asthma patients who have increased symptomatology at night (a significant portion) also tend to have disturbed sleep patterns and impaired daytime attention, concentration, and memory.¹

In 1998 it was estimated that asthma affected 17.3 million individuals in the United States and 150 million worldwide. From 1980-1995 the incidence of asthma in children under age 18 increased five percent per year, resulting in an increase of more than 100 percent in that time period, according to the National Health Interview Survey (NHIS), the mechanism the U.S. government uses to gather data regarding asthma prevalence and mortality. The current overall prevalence in children is estimated at 6.0-7.5 percent, with a total of over five million children affected. Asthma is the fourth-leading cause of disability in children, and one of the most common reasons for school absenteeism. The prevalence in adults is approximately five percent. Asthma prevalence among African-Americans is considerably higher than Caucasians or Hispanics, with black children having a 26-percent greater incidence than white children in 1995-1996.

Approximately 5,000 people die each year due to asthma. Across racial and socioeconomic groups, the death rate from asthma mirrors the incidence, with African-Americans having the highest mortality from this disease. The death rates for asthma are higher in the inner city and in lower socioeconomic groups. The exact cause of these differences might be due to genetic, socioeconomic, and/or access to health care issues. Direct costs (doctors' visits, hospitalization, drugs, etc.) and indirect costs (work and school absenteeism, etc.) of asthma vary, depending on the reference, but are estimated to be approximately \$6 billion per year.

Why the ever-increasing incidence of asthma in the last three decades? Some blame new home construction in the 1970s, when higher fuel costs prompted the construction of more airtight homes. Newer houses are more insulated and have less air exchange than older homes. Wall-to-wall carpet is much more common, as is central heating. Synthetic building materials laden with chemicals also enjoy greater utilization by builders. These "improvements" in construction make for a more closed micro-environment that has insufficient fresh air and is more conducive to the growth of microorganisms.

Other researchers point the finger at environmental pollutants. Industrialization of countries and the use of fossil fuels have paralleled the incidence of respiratory disease. There is good evidence that the increases in ozone, nitrogen dioxide, sulfur dioxide, and particulates in the atmosphere have exacerbated allergic diseases, including asthma, due to irritant effects of these substances causing chronic inflammation, as well as interactions with allergens and amplification of allergic reactions.^{2,3}

Changes in diet – including an increased intake of omega-6 fatty acids and a decreased intake of nutrients such as magnesium – and altered intestinal microflora are also hypothesized as contributors to the increased incidence of asthma.^{2,4,5}

There is also the possibility that the practice of vaccinating children has contributed to this increase in asthma incidence, although presently this theory has not been studied thoroughly. Investigators in New Zealand, which has one of the highest rates of asthma in the world, found that 23 children who had not been immunized with the diphtheria/tetanus/pertussis (DPT) and polio vaccines had no episodes of, or physician consultations for, asthma, whereas a group of immunized children had a 23-percent incidence of asthma.⁶ Researchers in England note similar results in a survey of 446 children. In a group of 203

children who had not been immunized for pertussis, two percent had a diagnosis of asthma at eight years of age, compared to 11 percent of 243 who had been vaccinated for pertussis ($p=0.0005$).⁷ However, Swedish researchers did not find this connection in a study of 9,000 children given either DPT or only the DT components.⁸

The Role of Inflammation in Asthma

The underlying pathophysiology of asthma, regardless of allergic components or triggering mechanisms, is airway inflammation. At the center of this improper inflammatory reaction is the T-cell. There is increasing evidence that the underlying process driving and maintaining the asthmatic inflammatory process is an abnormal or inadequately regulated CD4⁺ T-cell immune response to otherwise harmless environmental antigens. The major CD4⁺ T-cell subset involved in this process is the CD4⁺ Th2 subset, which produces a series of cytokines (secondary messaging molecules), including interleukin-4 (IL-4), IL-5, IL-6, IL-9, IL-10, and IL-13 (Table 1). These cytokines stimulate the growth, differentiation, and recruitment of mast cells, basophils, eosinophils, and B-cells, all of which are involved in humoral immunity and the allergic response. The other subset of CD4⁺ cells is the Th1 cell, which is responsible for production of interferon

Table 1: Cytokines Produced by Th1 and Th2 Cells.


Th1	Th2
TNF - α	IL - 3
IFN - γ	IL - 4
IL - 1	IL - 5
IL - 2	IL - 6
	IL - 9
	IL - 10
	IL - 13

gamma (IFN- γ) and interleukin-2 (IL-2), which are involved in delayed hypersensitivity responses and cellular immune responses to intracellular parasites and viruses. It is not yet known precisely why individuals with asthma have this overriding Th2 activity. It may be that genetics, viruses, fungi, heavy metals, nutrition, and pollution all contribute to this debilitating and sometimes deadly disease process (Table 2).

Antigen-specific IgE is partly responsible for initiation of an allergic response in asthma. Antigens cross-link with IgE on mast cells, which then spill their contents (histamine, leukotrienes) and further amplify the inflammatory response by damaging local tissue and attracting other lymphocytes. The regulation of IgE production involves interactions between antigen-presenting cells, and B and T lymphocytes. Antigen-presenting cells such as macrophages and dendritic cells present an antigen to CD4⁺Th2 cells, which secrete cytokines that magnify the immune response. IL-4 produced by Th2 cells stimulates IgE production in B-cells, while IL-5 stimulates eosinophil differentiation and mobilization to inflammatory sites (Figure 1). IL-10 enhances the growth and differentiation of mast cells and – very importantly – inhibits the production of IFN- γ . It appears the presence of excess IL-4 can also “switch” cytotoxic CD8⁺ cells from their

Table 2: Inducers of Th2 Activity.

Genetics
Microorganisms
RSV
Yeast/Fungi
Chlamydia?
Pertussis vaccination?
Heavy Metals
Lead
Mercury
Zinc deficiency
Pollution

Figure 1: Interactions of Th2 Cells with Other Cells.

LTD₄, and LTE₄, also attract leukocytes, in addition to their involvement in broncho-constriction and mucus production. The end result of these complex interactions is a cascading immune and inflammatory response characterized by airway eosinophilia, mucus hypersecretion, and airway hyper-responsiveness – the hallmarks of asthma.

Etiologic Factors in Asthma Allergies

Although asthma is a multifactorial condition, the strongest risk factor in the etiology of asthma is atopy (allergies, atopic dermatitis, allergic rhinitis).

An atopic individual has a significantly greater probability of developing asthma, and persons with a family history of atopic disease are at greatest risk. It is accepted that an immunological response to various allergenic stimuli, including pet dander, dust mites, cockroaches, fungi, and foods is a major triggering factor in asthma symptomatology.

Estimates of the number of people with asthma who also have allergic rhinitis are as high as 80 percent.¹⁹ Some practitioners suggest they are the same malady, only in different areas of the respiratory tract and should be treated similarly.¹⁹ In one study, 79 percent of individuals with asthma also had chronic rhinosinusitis.²⁰

Dust mites

Indoor allergens are numerous; however, dust mites (*Dermatophagoides pteronyssinus*) contribute greatly to the overall antigenic load in asthmatic individuals. The

normal production of IFN- γ (which promotes antiviral and antitumor activity) to production of IL-4 and IL-5, further augmenting inflammatory activity.⁹⁻¹⁸

The inflammatory process is also promoted when histamine and leukotrienes are released by mast cells. Histamine acts very quickly and stimulates bronchoconstriction and excess mucus production. After the initial release of histamine, mast cells and other leukocytes manufacture and release leukotrienes, eicosanoid molecules that also enhance the inflammatory response. In this late-phase response, leukotrienes – lipid-based molecules created by the action of the enzyme 5-lipoxygenase on arachidonic acid in cell membranes – exacerbate the broncho-constriction brought on by histamine. Leukotriene B₄ (LTB₄) is a very potent mediator of bronchoconstriction and chemotaxis. The cysteinyl leukotrienes – leukotrienes bound to the amino acid cysteine – which include LTC₄,

average home provides optimal temperature, humidity, and other environmental conditions for dust mite growth and reproduction, although dust mites appear in greater numbers in warm, humid climates. Dust mite feces are the major antigenic component, containing at least 10 antigens. A number of epidemiological studies have shown a correlation between dust mite exposure and asthma symptoms.²¹⁻²⁴ A Swedish study found significantly greater risk for asthma symptomatology in homes with higher levels of dust mites.²⁵ A U.S. study of inner-city children with asthma discovered a high proportion of these children had both a significant exposure and an immunological sensitization to dust mites and cockroaches.²⁶

Dust mite allergenicity could be at least partly due to enzymes in dust mite feces, which when inhaled can interrupt tight junctions between epithelial cells in the lungs. This disruption of the normal epithelial barrier can subsequently enhance the presentation of antigens (dust mite and others) to dendritic cells residing beneath the airway epithelium and facilitate immune response to those antigens. Such a mechanism would to some extent explain commonly-occurring allergenic responses to other inhalant antigens in individuals exposed and sensitized to dust mites.²⁷

The allergic response to dust mites involves an immediate hypersensitivity response, including increases in specific IgE antibodies and T-cells of the Th2 phenotype. Inhalation challenge of the allergic individual with dust mite antigen produces airway hyper-reactivity and bronchospasm, along with an eosinophil-dominated inflammatory response.

Preventive hygienic measures to reduce dust mite exposure include washing bedding in hot water, eliminating carpet where possible, and encasing mattresses and pillows in occlusive covers. The use of high efficiency particulate air (HEPA) filters in heating, ventilation, and air conditioning systems is also helpful, as is the use of a vacuum cleaner with

an on-board HEPA filter to clean floors and upholstery.²⁸

Cockroaches

As with dust mites, cockroaches can be a very significant allergen source in the allergic asthmatic. It is thought that cockroach antigens (from the body and feces) pose a significant threat to individuals with asthma, and may be partially responsible for the greatly increased morbidity and mortality from asthma in inner-city residents. Results of The National Cooperative Inner-City Asthma Study (NCICAS) demonstrate the degree of exposure to cockroach antigen, measured in bedroom dust, is directly correlated with a sensitized child's risk of hospitalization.²⁹

Dog and Cat Dander

Dogs and cats are another significant source of antigenic stimuli in the home, and can initiate or aggravate airway inflammation and asthma symptoms.³⁰ Cat dander tends to be more antigenic, as the allergen (which derives from salivary and sebaceous glands) is quite small, and thus can stay airborne for long periods of time. Conversely, dog allergen is larger and tends not to be airborne as much as cat allergen, making it more likely cat allergen will be inhaled.³¹

In a study involving 787 asthmatics, the presence of domestic animals in the home was one of the most significant predictors of asthma morbidity;³² other studies have confirmed these results.³³⁻³⁵ An interesting study was conducted in Los Alamos, New Mexico, which is at 7,200 feet elevation. At this altitude, household dust does not contain high levels of dust mite antigens. Among school children in this community with asthma, (n=57) sensitization to cat and dog allergens was strongly associated with bronchial reactivity and asthma symptoms, while mites, cockroaches, and pollens were not significantly associated with asthma symptoms.³⁶

Unfortunately, strict avoidance of animal allergens is practically impossible, because even if domestic animals are not in the home there is still a possibility of significant exposure due to transfer of animal dander in public places. Studies of cat and dog allergens in Swedish schools discovered high concentrations of these allergens in school dust.^{37,38} Perzanowski et al found allergen levels higher than those found in homes without pets and noted, "The schools appear to be a major site of exposure to cat and dog allergens."³⁸ Significant levels of cat and dog allergens were also found in public waiting areas of a British hospital, although vacuuming three times per week decreased allergen levels in upholstered chairs.³⁹ Bathing animals can also be helpful in reducing the amount of allergen transfer. According to a recent British study, washing the pet dog twice per week can decrease airborne canine allergen 84 percent.⁴⁰

It is vital to reduce total allergenic load, if possible. If a pet lives in the house, maximizing the time the animal spends outdoors is a must. Animals must not be allowed into the bedroom, which should be considered a "clean room" that has as few allergens as possible. This provides the asthmatic an environment that is as free as possible from allergens for at least eight hours out of 24. HEPA filters are a helpful adjunct in reducing the allergenic load from animal dander in the home.⁴¹

Food Allergy

Asthma can also be caused or exacerbated by food allergy. It is probably not as important a causative factor as inhalant allergies, but nevertheless contributes to the overall allergenic load of the asthmatic. Some estimates are that 5-8 percent of people with asthma have a food allergy that can be confirmed via a double-blind, placebo-controlled food challenge.⁴²⁻⁴⁶ Patient estimates of food allergy in asthma are much higher, ranging from 20-60 percent.^{45,46} Many who make dietary modifications to avoid foods they believe

are causing asthmatic symptoms feel those modifications help their asthma, including 79 percent of asthma patients in one study.⁴⁵

Atopic individuals produce specific IgE antibodies to food proteins, which bind primarily to mast cells and basophils. When the person comes in contact with the allergic food, histamine is released by these cells, stimulating an inflammatory response in the lungs, and asthma symptoms ensue. This reaction, or the involvement of non-IgE-mediated reactions, can be immediate or may take hours or days to manifest. This might be one reason why estimates of food allergy in asthma patients are low, as researchers often look for symptoms to appear quickly following challenge; whereas, with a delayed reaction to foods, it is more difficult to assess the cause of the symptoms.

Gastrointestinal symptoms occur more frequently in children with asthma and atopic dermatitis;⁴⁷ and abnormal gastrointestinal permeability is found in a greater percentage of asthmatics compared to non-asthmatic controls.⁴⁸ It is possible there is a common defect in the respiratory and gastrointestinal mucosa, either caused by the asthma or as a possible cause of asthma. Increased gastrointestinal permeability can allow large antigenic molecules to be absorbed through the mucosa, causing sensitization to foods. Possibly the increased permeability in the lungs caused by dust mite antigen causes a similar increase in transfer of antigenic material across the respiratory epithelium.²⁷

Although the role of food allergies as a causative factor in asthma remains ambiguous, it seems some individuals do benefit from avoidance of identified problem foods. This option should not be overlooked in dealing with asthma.

Yeast/Fungi

Fungi are known to be causative factors that induce asthmatic symptoms. Outdoor airborne fungi, including *Cladosporium*,

Alternaria, *Penicillium*, and *Aspergillus* are significant triggers of IgE formation, as are the indoor fungi *Aspergillus*, *Neurospora*, and *Eurotium*. In addition, some practitioners believe there is a strong fungal/yeast component in the lung and/or gut microflora in individuals with asthma.^{31,49,50} Ridding the home or work environment of these organisms and utilizing antifungal treatments as appropriate has been reported to improve asthma symptomatology.

Subjective symptoms and peak expiratory flow (PEF) in 74 children with asthma were followed for 16 weeks, and correlated with the amount of bacterial endotoxin and fungal 1,3-beta glucan levels present in house dust. After adjusting for pet presence, type of floor cover, and dust mite allergen levels, yeast levels were positively correlated with PEF variability in these children.⁵¹

Sensitivity to fungal allergens has also been found to be a risk factor for severe life-threatening asthma. A New Zealand study of patients admitted to a hospital intensive care unit (ICU) revealed that patients admitted to the ICU had a significantly greater incidence of reactivity to *Alternaria tenuis*, *Cladosporium cladosporoides*, *Helminthosporium maydis*, or *Epicoccum nigrum* (54% vs 30% for other groups not admitted to the ICU or not hospitalized for asthma).⁵²

Fungal cultures were performed from bronchial secretions of 13 asthma patients and from the skin of 91 patients with atopic dermatitis. The predominant yeast species present on the skin were *Candida* and *Rhodotorula* species, while *Candida* species were the most prominent species isolated from bronchial secretions.⁵³ *Candida albicans* may well be a prominent allergen for people with asthma. The cell wall constituent, mannan, and acid protease – an enzyme secreted by *C. albicans* – are both highly allergenic, and serum IgE antibodies are often increased in atopic individuals.^{54,55}

Animal and *in vitro* studies suggest if there is an imbalanced Th1/Th2 ratio of immune activity, *Candida* infection is more likely to occur.⁵⁶⁻⁶⁰ There has been little investigation to date as to whether asthmatics are more likely to have *Candida* infections because of Th2-dominance, or whether *Candida* infection predisposes an individual to experience asthma symptoms. What data there is suggests both may be true.^{49,50,61,62} Regardless, these data suggest that environmental fungi and/or colonization with *Candida* or other organisms probably contribute to asthma severity. Environmental eradication of fungi, as well as internal antifungal agents, should be considered in those testing positive for reactivity to these organisms.

A Probable Connection to Persistent Viruses and Chlamydia

The search for etiologic agents in bronchial asthma has brought some researchers to believe viruses or other organisms might be partly responsible for some asthma cases. Infections with common cold viruses and influenza frequently precipitate symptoms in those with established asthma. The chief mechanism for these exacerbations appears to be viral replication in respiratory epithelial cells triggering cytokine release, inflammation, and mucus production. These processes are necessary to clear the viral infection; but superimposed over a pre-existing inflammatory condition in the airways they can trigger symptomatology.

There is evidence that some viruses may, in the presence of IL-4 (produced in excess by Th2 cells in asthmatics) cause CD8⁺ cells to drastically reduce their usual secretion of IFN- γ and switch to production of IL-4 and IL-5. This switch to greater Th2 activity can slow the immune system's clearance of the virus, cause pulmonary eosinophil infiltration, and exacerbate asthma inflammation.¹⁸

Marin et al reported that 39 of 50 (78%) presently asymptomatic asthmatic

children harbored adenovirus DNA in their nasopharynx, detected from nasal swabs, while the virus was found in only one of 20 controls (5%). Rhinovirus was found in 16 asthma patients (32%), and none of the controls. The authors believe the presence of these viruses in patients, but not controls, might reveal a possible connection between viral infections and asthma.⁶³

It also has been hypothesized that *Chlamydia pneumoniae* infection might predispose individuals to asthma. A recent review on this subject examined papers over a 15-year period; epidemiological studies and case reports were included. The authors found significant epidemiological associations between Chlamydia infection and asthma, as well as reports of clinical improvement following antibiotic treatment for this organism.⁶⁴ A study of children and young adults with asthma found the opposite – higher IgG titers for Chlamydia were correlated with a reduced risk of asthma.⁶⁵ Another study related high IgG and IgA titers with lower FEV1 (Forced Expiratory Volume in One Second – an objective measurement of airflow); i.e., higher titers of antibodies to Chlamydia were associated with increasing severity of asthma in adults.⁶⁶ There is possibly a difference in how Chlamydia might affect children compared to adults, which might explain the disparity in these results.

Another virus with a possible link to asthma symptoms is respiratory syncytial virus (RSV). Wheezing is a cardinal sign of acute RSV infection in infancy, and may persist chronically for years after an acute infection. In a 10-year follow-up of children hospitalized due to RSV infection, 40 percent reported wheezing at five years (11 percent in controls), and 22 percent reported wheezing at 10 years (10 percent in controls).⁶⁷ A Brazilian study confirms these findings, demonstrating a significantly increased risk for wheezing at age six in children who had RSV before age three. The risk for wheezing decreased with

increasing age, becoming insignificant by age 13.⁶⁸ These studies show that, while RSV infection in a young child is a significant risk factor for wheezing until ages 10-13, it does not pose a significant risk for asthma symptoms in adults. It has been proposed that RSV infection stimulates an over-active Th2 cytokine response^{69,70} which, as noted above, predisposes toward eosinophilia and hyper-reactive airways (Table 2).

Indoor and Outdoor Air Pollution

An increase in inhaled particulate matter, whether from cigarette smoking, environmental tobacco smoke, fossil fuels, or wood burning stoves can exacerbate asthma symptoms. Recent animal research reveals second-hand smoke up-regulates the Th2 immune response. This mechanism might partially explain epidemiological evidence linking second-hand smoke with asthma prevalence.⁷¹ Use of gas appliances in the home can increase the concentration of nitrogen dioxide in inspired air, correspondingly reducing lung function. Volatile organic compounds and formaldehyde in the indoor environment, from off-gassing of paints, adhesives, furnishings, and building materials can also increase the risk of asthma attacks. An excellent review of the subject of asthma and the home environment can be found in Jones' recent article in the *Journal of Asthma*.³¹

Does Heavy Metal Toxicity Promote Inflammation in Asthma?

Lead and mercury toxicity has been shown in animal studies to inhibit Th1 cells and stimulate a Th2 immune response and, in some animals, promote autoimmune diseases.^{11,72} In humans, if heavy metals were proven to cause an imbalance in the normal Th1:Th2 ratio, it would explain practitioner reports of improvements in asthma symptoms after heavy metal detoxification.

Gastroesophageal Reflux: a Possible Connection

Another possible contributor to the etiology of asthma is gastroesophageal reflux (GER). An increased incidence of GER has been noted in asthma patients;^{73,74} however, it is not fully understood if these conditions simply overlap, if GER causes or exacerbates asthma, or if asthma causes GER. In his 2000 review, Sontag⁷⁴ estimates that approximately 75 percent of asthmatic patients experience GER symptoms, 80 percent have abnormal acid reflux, 60 percent have a hiatal hernia, and 40 percent have esophageal damage (erosions or ulcerations). Two mechanisms have been proposed to explain how GER might cause asthma symptoms: (1) a vagal-mediated reflex from the irritated esophagus to the lung, causing reflex bronchoconstriction, or (2) microaspiration of gastric acid, causing pulmonary irritation, injury, and subsequent overproduction of mucus.

Proponents of the vagal reflex theory note that the esophagus and lungs share the same embryonic tissue and innervation. An irritated esophagus could, therefore, initiate a vagal reflex, resulting in increased bronchial reactivity.⁷⁴⁻⁷⁹ Animal and human studies have shown increased pulmonary airway resistance with esophageal acid infusion. This bronchoconstriction was reversed with antacid therapy⁸⁰ or surgical interruption of the vagus nerves.⁷⁴ In a small study of pediatric asthma (n=9), acid was infused into the esophagus during sleep, causing bronchoconstriction only in the four children with previously diagnosed esophagitis (positive Bernstein test). These results led the researchers to comment that reflux, an irritated esophagus, and a low nocturnal threshold to bronchoconstrictive stimuli were all necessary for reflux to cause bronchoconstriction. It is interesting to note that, in this study, acid did not cause bronchoconstriction during a midnight infusion, but did in the 4-5 a.m. infusion.⁷⁸ In a

study of 47 adults (20 asthmatics with reflux, 7 without, 10 participants with GER, and 10 controls) esophageal acid infusion caused a significant decrease in PEF in all participants; however, the group of asthma patients with reflux had a greater decrease in PEF, as well as further deterioration after the acid was cleared with normal saline. The authors stated that since there was no microaspiration of acid, a vagally mediated reflex must be involved.⁷⁷ Subsequent studies found increased vagal responsiveness in patients with asthma and GER; this was blocked by atropine, which inhibits vagal stimulation.^{81,82}

Animal and human studies have provided evidence for the microaspiration theory of GER, although overall the evidence looks less convincing than the "reflex theory." Inhalation of a dilute acid solution in cats caused significantly greater bronchoconstriction than infusion of acid into the esophagus.⁸³ Ambulatory esophageal pH monitoring and scintigraphic technetium monitoring have provided documentation of esophageal acid reflux and microaspiration of gastric acid in humans.^{84,85} It might be that asthma related to GER is a multifactorial problem, with components of microaspiration and gastroesophageal reflux.

If indeed GER causes asthma or exacerbates hypersensitive respiratory tissue, the true test should be that anti-reflux or antacid therapy significantly improves asthma symptoms. However, antacid therapy, which has consisted mostly of H2 blockers (cimetidine, ranitidine) or a proton pump inhibitor (omeprazole), has not been consistently effective, showing mixed results.⁷⁴

A small study (n=5) of asthma patients with nocturnal symptoms and GER determined that treating asthma with ephedrine improved asthma symptoms as well as reflux symptoms. The authors stated the bronchodilation provided by the ephedrine and the subsequent improvement in GER symptoms suggests GER might be a result of asthma symptomatology, not the opposite.⁸⁶

The most common GER therapy is a pharmacological reduction in gastric acid output. However, Wright found a substantial number of children with asthma actually have a reduction in gastric acid output. He theorizes that reduced gastric output results in inadequate protein digestion and an increase in allergenicity of foods, as well as a reduction in nutrient absorption. Treatment with hydrochloric acid supplementation is part of his integrated treatment protocol, and is claimed to provide symptomatic improvement.^{87,88}

The Possible Role of Dehydration in Asthma

It is important to ensure the asthma patient is well hydrated; however, good data does not exist showing a firm association between dehydration and asthma, except in exercise-induced asthma (EIA). In EIA, dehydration of airway epithelial cells may contribute to epithelial damage, edema, and hyper-responsiveness.⁸⁹⁻⁹³ This does not rule out the possibility that chronic sub-clinical dehydration may contribute to asthma-related symptoms; in fact, it lends credibility to the theory.

Aspirin-induced Asthmatic Exacerbation

A subset of individuals with asthma experience symptoms after ingestion of aspirin or other similar non-steroidal anti-inflammatory drugs (NSAIDs). Since most NSAIDs block the enzyme cyclooxygenase, it is thought this leaves more arachidonic acid to react with the other arm of the eicosanoid pathway, regulated by activity of lipoxygenase. Downstream metabolites of this pathway include the leukotrienes, very potent stimulators of inflammation and bronchial constriction. Avoidance of NSAIDs is imperative in these individuals. Some asthmatics also react to sulfites present in some foods and wines. This reaction is more common in people who experience symptoms following ingestion of NSAIDs.⁹⁵

The Emotional Connection

It is often said that asthma can be triggered by emotional stress. In fact, traditional Chinese medicine refers to the lungs in connection with grief and sorrow. Asthma patients have been noted to have a more negative affect, and emotional upheavals have been linked to asthma symptom exacerbations. In a recent study, Cetanni et al⁹⁵ examined 80 patients with asthma, 40 patients with either hepatitis B or C, and 40 healthy controls. Significantly greater anxiety and depression were found in asthma patients compared to hepatitis patients and controls. In a study of 230 patients with asthma, 45 percent scored high enough on depression ratings scales to be considered depressed. Those with more depressive symptoms reported worse health-related quality of life than asthma patients without depression.⁹⁶ This begs the question, do a significant number of asthma patients have anxiety and depression because of their asthma, or do these psychological diagnoses predispose one to asthma symptoms? It may be a combination of both. No doubt it is an anxiety-producing feeling when one cannot get enough air. Conversely, intense emotions can bring about asthma symptoms. Increased respiratory resistance, airway reactivity, shortness of breath, and decreased peak expiratory flow rate have been reported after an emotional challenge.⁹⁷⁻⁹⁹

Nutrients and Asthma

Vitamin C

There is reason to believe oxygen radicals are involved in the pathophysiology of bronchial asthma. Inflammatory cells generate and release reactive oxygen species,¹⁰⁰ and inflammatory cells from asthma patients produce more reactive oxygen species than non-asthmatics.^{101,102} Significantly decreased levels of vitamin C and vitamin E were found in lung lining fluid of asthmatics in a recent study, even though plasma levels were normal.¹⁰³ Fourteen children with asthma were found to

have significantly decreased serum levels of vitamin E, beta-carotene, and ascorbic acid during an asymptomatic period, with elevated levels of lipid peroxidation products during an asthma attack.¹⁰⁴ To combat the increased oxidant burden in asthmatics, the attainment and maintenance of optimal levels of antioxidant nutrients might be essential

Epidemiological studies of vitamin C intake and asthma symptoms and respiratory function note a beneficial overall effect of vitamin C. Generally, as vitamin C intake rises, FEV1 and FVC (forced vital capacity) increase.¹⁰⁵⁻¹⁰⁸ Yet the effect of vitamin C on asthma remains controversial, as studies on vitamin C supplementation in asthma patients have yielded contradictory results. For example, asthma patients subjected to methacholine challenge testing alone and after ascorbic acid supplementation (1 g one hour prior to challenge) were able to withstand greater doses of methacholine after vitamin C dosing.¹⁰⁹ In this test, methacholine, a bronchoconstricting drug, is inhaled. In those with hyper-reactive airways, there will be a greater constriction of pulmonary smooth muscle and loss of lung function. However, short-term dosing with ascorbic acid failed to improve bronchial hyper-reactivity with inhaled histamine challenge.¹¹⁰ Schachter and Schlesinger studied the effect of ascorbic acid on exercise-induced asthma, and concluded that ascorbic acid has a mild bronchodilatory effect in exercise-induced bronchospasm, seen as a protective effect on FEV1 and FVC compared to placebo.¹¹¹

Reviews regarding vitamin C and asthma point to the fact that the studies performed to date, whether showing positive or negative effects, utilized short-term vitamin C dosing, as if they were attempting to assess an immediate effect of vitamin C only, and not the effects of long-term optimal blood and tissue levels of this nutrient.^{112,113} Long-term supplementation studies of vitamin C, asthma symptomatology, and pulmonary function

need to be conducted to further elucidate vitamin C's role in asthma treatment.

Vitamin B6

Pyridoxal 5'-phosphate (PLP), the active form of vitamin B6 in the body, is involved in numerous biochemical processes, and has been found in lower concentrations in asthma patients.¹¹⁴ However, investigations of the therapeutic efficacy of B6 supplementation have resulted in mixed results. Treatment of asthma with pyridoxine (50 mg twice daily) resulted in improvements in a reduction of asthma exacerbations and wheezing episodes in adults.¹¹⁴ In 76 children with asthma, B6 supplementation (100 mg pyridoxine HCl twice daily) resulted in fewer bronchoconstrictive attacks; less wheezing, cough, and chest tightness; and less use of bronchodilators and steroid medications.¹¹⁵ A double-blind trial of B6 (300 mg/day pyridoxine HCl) in steroid-dependent asthma patients resulted in no change in lung function.¹¹⁶

Asthma patients treated with the bronchodilator theophylline have lower blood levels of PLP, possibly due to PLP depletion secondary to its use in theophylline metabolism. Theophylline is not used as much as it once was, mostly due to side effects and its narrow therapeutic range;^{117,118} however, monitoring of vitamin B6 levels and supplementation if warranted should be considered for individuals using this drug.

Vitamin B12

It has been reported that children with asthma may be B12 deficient, although there is no peer-reviewed literature to corroborate such a statement. Jonathan Wright, MD, and Alan Gaby, MD, relate that asthmatic children respond well to B12 supplementation, particularly if they are sulfite-sensitive. Daily doses of 1000-3000 mcg may be needed.¹¹⁹

Magnesium

Magnesium is a cofactor in over 300 biochemical processes in the body, and is especially vital to the contraction/relaxation state of smooth muscle. Magnesium and calcium work in concert to regulate the contraction and relaxation of smooth muscle. Low magnesium enhances the contraction activity of calcium, while higher magnesium levels inhibit calcium and promote relaxation. Hypomagnesemia is common in asthmatics,¹²⁰⁻¹²³ and worsens in more severe cases.^{120,121}

Serum levels are often used to assess magnesium status; however, serum magnesium can be normal while intracellular magnesium is deficient. Intracellular assessment utilizing erythrocytes or leukocytes is recommended for an accurate depiction of magnesium status. Intracellular magnesium was assessed in 22 asthma patients and compared with 38 controls with allergic rhinitis. Magnesium levels were significantly lower in individuals with asthma versus controls. Lower intracellular magnesium was correlated with increased airway hyper-reactivity via the methacholine challenge test. Magnesium levels did not significantly affect FEV1.¹²² Similar findings were recently reported by Hashimoto et al.¹²¹ While low magnesium status is a consistent finding, the role of magnesium supplementation is more ambiguous.

A large British study of dietary magnesium intake and asthma symptoms in 2,633 people found individuals who had a greater dietary intake of magnesium had a significantly higher FEV1 and significantly decreased airway hyper-reactivity.¹²⁴ In a randomized, double-blind, placebo-controlled crossover study, Hill et al reported significantly fewer asthma symptoms and reduced subjective bronchial hyper-reactivity in patients given 400 mg magnesium per day as a dietary supplement. However, objective measurements of pulmonary function were not significantly better in the three-week study, and use of short-acting beta agonist inhaler

medications was not decreased.¹²⁵ It might be that a three-week trial, while seeming to improve aspects of patient subjective symptomatology, is not long enough to have a long-term stabilizing effect on pulmonary function. An investigation on the effects of long-term magnesium supplementation to correct tissue levels of this mineral seems warranted.

Intravenous magnesium sulfate is a critical treatment component for severe asthma seen in the emergency department in many hospitals. Intravenous magnesium often relieves symptoms soon after infusion is begun,¹²⁶ and can decrease the need for intubation in status asthmaticus¹²⁷ and respiratory failure.¹²⁸ In recent pediatric studies, addition of magnesium sulfate IV to standard emergency care initiated faster improvement in PEF and oxygen saturation in patients not responsive to conventional treatments.^{129,130}

Another pediatric study of 30 patients with an acute asthma exacerbation used a high-dose protocol of 40 mg/kg magnesium sulfate infused over a 20-minute period. Significant improvement was noted at 20 minutes, and a much greater improvement was noted at 110 minutes: PEF had improved 26 percent (vs. 2% in saline controls), FEV1 24 percent (2%), and FVC 27 percent (3%). All results were highly significant ($p < 0.001$).¹³¹

Acute administration of intravenous magnesium has been studied as a stand-alone therapy, as well as an adjuvant to conventional beta-adrenergic, methyl xanthine, and steroid treatment. Results have been mixed, with some studies finding statistically significant improvements in lung function¹³⁰⁻¹³⁴ and others determining that IV magnesium sulfate is not helpful.^{135,136} In two recent reviews of the subject, IV magnesium sulfate was found in one review to be of significant benefit to patients with severe asthma,¹³⁷ and found not to affect treatment outcomes in a meta-analysis.¹³⁸

It is unknown why these various investigations resulted in diverse outcomes.

Some intravenous trials used 1-2 g magnesium sulfate alone, while others used a similar dose as an initial bolus, followed by slower drips over the next few hours. There does not seem to be a pattern of results following a specific type of protocol. Regardless of the inconsistent results seen with IV magnesium sulfate, asthmatics do tend to have lower intracellular levels of magnesium, and supplementation to correct those levels seems warranted.

Zinc

There is little direct evidence of zinc deficiency causing asthma symptoms, but asthma patients have been shown to have lower plasma zinc than healthy controls.¹³⁹ Serum and hair zinc were significantly lower in individuals with asthma and atopic dermatitis.¹⁴⁰ Similar results were reported by Di Toro et al in asthmatics versus controls.¹⁴¹

It has been proposed that a zinc deficiency switches the Th1 immune response toward a Th2-type response, which, as mentioned earlier, is a hallmark of asthma pathophysiology.^{142,143} Prasad et al studied how mild zinc deficiency affects the immune system. Zinc deficiency caused an imbalance between Th1 and Th2 functions, with a subsequent increased production of IL-4, IL-6, and IL-10, and decreased production of IL-2, IFN- γ , and tumor necrosis factor alpha. They also noted decreased NK-cell activity and decreased numbers of cytotoxic CD8⁺ T-cell precursor cells.¹⁴⁴ In two other studies of zinc and immunity, individuals deficient in zinc exhibited diminished Th1 activity, but unaffected Th2 activity, creating a relative Th1 deficiency.^{145,146}

Even without the benefit of definitive research on long-term zinc supplementation in asthma patients, this author believes it is vitally important to ensure proper zinc nutrition in asthma patients to avoid a potential zinc-deficiency-induced exacerbation of asthma symptoms due to increased Th2 immune activity.

Selenium

Glutathione is a vital component of the body's antioxidant system. Glutathione peroxidase (GSH-Px) is the selenium-containing enzyme that uses glutathione as a cofactor to metabolize hydrogen peroxide, and can thus protect against oxidative damage. Individuals with asthma tend to have increased oxidative activity, lowered selenium status, and decreased activity of glutathione peroxidase.¹⁴⁷⁻¹⁵⁰

Only one study has been conducted on selenium supplementation to combat the increased pulmonary oxidative burden in asthmatics. Hasselmark et al performed a double-blind, placebo-controlled study in which asthma patients were given 100 mcg sodium selenite (containing 46 mcg elemental selenium) for 14 weeks. Significant increases were seen in serum and platelet selenium and GSH-Px activity, and improvements were seen in subjective symptomatology. However, objective measurements of lung function were not changed.¹⁵¹ It may be that the supplemental dosage given was too low and that a supplemental dose of 200-250 mcg might be more beneficial. More study is warranted in this important arena.

Omega-3 Fatty Acids

Intermediate and end-products of fatty acid metabolism are known to have potent effects on the inflammatory process. Prostaglandins and leukotrienes from arachidonic acid metabolism are highly inflammatory molecules, and play an important role in the pathophysiology of asthma. Arachidonic acid is released from cell membrane phospholipids of activated immune cells (via activity of the enzyme phospholipase A₂) in response to various immunological stimuli. Prostaglandins and leukotrienes resulting from arachidonic acid metabolism are pro-inflammatory molecules. Leukotriene B₄ (LTB₄) is involved in bronchoconstriction and leukocyte chemotaxis, while the cysteinyl leukotrienes – LTC₄,


LTD₄, and LTE₄ – are far more potent promoters of smooth muscle constriction and mucus production. An overabundance of these leukotrienes is implicated in the pathophysiology of asthma.

Research into the effects of leukotrienes has spurred the development of new drugs that block the activity of these potent substances. These drugs appear to be of benefit in some asthma patients, particularly those with more severe disease. Steroid medications, either inhaled or systemic via oral or parenteral dosing, have been the mainstay of anti-inflammatory asthma drug therapy. In contrast to the new leukotriene-inhibiting drugs, corticosteroids strongly inhibit the release of arachidonic acid from cell membranes

by blocking the activity of phospholipase A₂, resulting in a greatly diminished amount of prostaglandins and leukotrienes. Two LTD₄ receptor antagonists, zafirlukast and montelukast, have been approved for use in asthma and provide moderate improvements in objective lung function tests, as well as less reliance on inhaled steroid medications. A 5-lipoxygenase inhibitor, zileuton, has demonstrated similar results.^{152,153} Cromolyn sodium, used prophylactically in asthma, has been shown to inhibit LTE₄-induced bronchoconstriction, probably by inhibiting mast cell degranulation.¹⁵⁴

Cold-water fatty fish contain relatively large amounts of the omega-3 fatty acids eicosapentaenoic acid (EPA) and

Figure 2: Fatty Acids and Inflammation.



docosahexaenoic acid (DHA). When these fish are eaten, or when oil derived from them is taken as a supplement, EPA and DHA displace arachidonic acid from cell membranes. When these cells are stimulated they subsequently release relatively higher concentrations of fish-derived oils. The resultant downline metabolites of EPA and DHA differ from arachidonic acid metabolites. EPA and DHA are converted by cyclooxygenase into 3-series prostaglandins, and by lipoxygenase to 5-series leukotrienes, both categories of which are far less potent inflammatory mediators than the 2-series prostaglandins and 4-series leukotrienes arising from arachidonic acid metabolism^{155,156} (Figure 2). Because of this shift toward less inflammatory eicosanoids, one would expect to see less inflammatory activity in the lungs, and a subsequent improvement in asthma symptoms and lung function. Epidemiological studies of dietary fish intake and risk of asthma show an inverse correlation; i.e., more fish consumed equals less risk of asthma.^{157,158} However, the clinical data is equivocal, with well-designed studies showing both positive and negative results from omega-3 fatty acid supplementation.

A group (n=7) of individuals with seasonal asthma were supplemented with 3 g/d of a fish oil concentrate containing approximately 1,300 mg each of EPA and DHA, resulting in decreased residual volume (which is usually increased in asthma patients) and decreased bronchial reactivity.¹⁵⁹

Broughton et al studied 26 asthma patients after a one-month regimen of low- or high-dose omega-3 fatty acid intake. Patients' dietary intake of fish was evaluated, then supplementation was individualized for each patient so they ingested omega-3 and omega-6 fatty acids in a ratio of 0.1:1 or 0.5:1. This provided either 0.7 grams EPA/DHA or 3.3 grams EPA/DHA, respectively (the ratio of EPA to DHA in this study was not given). The high-dose protocol stimulated an improvement in bronchial reaction to methacholine

challenge in 40 percent of subjects, compared to a reduction in lung function in the low-dose group. Leukotriene B₅ was increased in the high-dose group and was predictive of lung function.¹⁶⁰ This seems to indicate a role for fish oil supplementation in asthma treatment.

In a separate study, after 10 weeks of supplementation with 3.2 g EPA and 2.2 g DHA per day, 12 subjects underwent histamine challenge, exercise challenge, and neutrophil studies to assess the efficacy of fish supplementation in asthma. Although there was a significant increase in omega-3 fatty acid content of neutrophils and a 50-percent inhibition of LTB₄ synthesis, there was no detectable change in the clinical outcome; e.g., no significant change in histamine response, exercise response, FEV1, or symptom score.¹⁶¹ Hodge et al reported similar results in their study of asthmatic children. After six months' supplementation with 1.2 g/d of omega-3 fatty acids, a five-fold increase in plasma EPA and a decrease in peripheral blood eosinophils was seen, but there was no change in symptom severity.¹⁵⁸ The reason for these mixed findings is not known.

Botanicals and Asthma

For botanicals to be effective in asthma treatment they should provide some symptomatic relief and optimally should have a significant effect on the pathophysiology of the disease; e.g., excess histamine release, leukotriene synthesis, imbalanced Th1/Th2 immune activity. A number of botanical medicines indicated for asthma are listed in various herbal compendiums. Expectorants such as Lobelia, Sanguinaria, and Grindelia are often used by herbalists, naturopaths, etc., and are reported to have some symptomatic benefit; however, no research on these plants with respect to efficacy in the treatment of asthma is available. Those botanicals and botanically-derived substances with some research explaining their mechanism and/or efficacy in asthma are discussed below.

Tylophora asthmatica

One botanical that has undergone clinical scrutiny and shown success in treating asthma is an Indian plant called *Tylophora asthmatica* (also known as *Tylophora indica* or Indian ipecac). The leaves of the plant are used in Ayurvedic medicine for the treatment of asthma, bronchitis, and arthritis. It can have an irritant effect on the gastrointestinal mucosa, and in large doses will act as an emetic. In smaller doses, however, it acts as an expectorant, anti-inflammatory, and may provide benefit in asthma cases.

Alkaloids from this plant have been isolated and identified as tylophorine and tylophorinine. These alkaloids are believed to be responsible for the plant's therapeutic efficacy. In a rat study, tylophorine inhibited systemic anaphylaxis, adjuvant-induced arthritis, and mast cell degranulation.¹⁶² It is suggested that *Tylophora* might have a direct effect on the adrenal glands, thus increasing endogenous steroid production and anti-inflammatory activity.¹⁶³

Ingestion of *Tylophora* leaf in asthma patients resulted in decreased nocturnal symptoms, as well as significant improvements in lung function indices compared to placebo in a double-blind, crossover study. These improvements continued for weeks beyond the short-term (7-day) trial period.¹⁶⁴ Similar long-lasting results were reported in a study of 110 asthmatics. These patients chewed and swallowed one *Tylophora* leaf per day for six days. At one week, 62 percent of individuals taking *Tylophora* had moderate to complete symptom relief, which lasted for weeks after the trial. A significant percentage of subjects complained of nausea, although there tended to be a positive correlation between nausea and degree of symptomatic improvement.¹⁶⁵ To date, no nutrient or other botanical has demonstrated a similar long-lasting effect after short-term dosing.

Boswellia serrata

The gum resin of *Boswellia serrata*, also known as frankincense, has been used in Ayurvedic medicine for centuries, and is also known in that system of medicine as Salai guggul. Leukotrienes are elevated in asthma and are a major component of inflammation and bronchoconstriction. The 4-series leukotrienes (LTB₄, LTC₄, LTD₄, LTE₄) are derived from arachidonic acid in cell membranes via activity of the enzyme 5-lipoxygenase. Components of *Boswellia* called boswellic acids have been found to specifically inhibit 5-lipoxygenase.¹⁶⁶ In animal studies, *Boswellia* not only inhibited LTB₄ production,¹⁶⁷ but also prevented leukocyte migration to inflammatory sites.¹⁶⁸

Due to 5-lipoxygenase inhibition, *Boswellia* should be a beneficial component of asthma therapy. A double-blind, placebo-controlled study of *Boswellia* in asthma looked at just this issue. Forty patients were treated for six weeks with a *Boswellia* extract (300 mg three times daily). Symptomatic improvement (dyspnea, wheezing) was seen in 70 percent of patients, as were objective measurements of lung function (FEV1, FVC, PEF). A reduction of eosinophilia was also noted. Twenty-seven percent of participants in the placebo group showed improvement.¹⁶⁹ This is a very promising study, showing both subjective and objective improvement in asthma. The new anti-leukotriene medications block leukotriene receptors, whereas *Boswellia* blocks the formation of leukotrienes. Either way, the end result should be a decrease in leukotriene-induced inflammation and bronchoconstriction.

Quercetin

Quercetin is one of the most widely occurring flavonoids ingested in food by humans. It has been demonstrated to have potent anticarcinogenic, anti-inflammatory, and antioxidant capacity. In experimental

study, quercetin reduced the concentration of prostaglandin E₂ and LTB₄ in pleural exudate of rats given carrageenan intrapleurally.¹⁷⁰ This points to a possible inhibition of either phospholipase A2 – the enzyme involved in release of arachidonic acid from cell membranes – or inhibition of cyclooxygenase and lipoxygenase. Quercetin also inhibits mast cell degranulation and subsequent release of histamine.^{171,172} Clinical studies of quercetin use in asthma are lacking; however, this flavonoid is probably useful in the overall treatment due to its antihistaminic activity. Due to the poor bioavailability of quercetin,¹⁷³ this author utilizes a water-soluble quercetin analogue – quercetin chalcone.

Plant Sterols and Sterolins

One of the basic biochemical dysfunctions in asthma is an increase in IgE and specific T-cell activity. The overactivity of Th2 cells produces increased IgE antibody formation, chemotaxis of neutrophils, eosinophilia, and a subsequent improper immune and inflammatory response.

One of the most intriguing and promising adjuncts in the treatment of asthma are plant sterols and sterolins (sterol glycosides). A proprietary blend of these plant lipids (in a ratio of 100:1) has been shown *in vitro* and *in vivo* to increase Th1 activity while dampening Th2. This has been studied in animals and humans in chronic viral infections, tuberculosis, and HIV. Clinical studies are ongoing with this compound on rheumatoid arthritis, HIV, hepatitis C, human papilloma virus, and asthma/allergic rhinitis.¹⁷⁴⁻¹⁷⁷ While the mechanism of action of plant sterols and sterolins is intriguing, and while anecdotal reports of this compound's efficacy in asthma treatment are encouraging, research-based evidence is currently lacking.

Petasites hybridus

Petasites hybridus, also known as butterbur, was used historically by the Greeks

in the treatment of asthma, and most recently in clinical studies for migraines.¹⁷⁸ Cell culture studies have shown an extract of this plant inhibits leukotriene synthesis, possibly by inhibition of 5-lipoxygenase.^{179,180} A recent study on guinea pig trachea tissue revealed a concentration-dependent inhibition of histamine and leukotriene-induced contraction in this tissue upon introduction of this compound.¹⁸¹ In an open study of 70 asthma and chronic bronchitis patients, a single dose of Petasites (600 mg powdered rhizome) resulted in significant improvements in FEV1 and bronchial reactivity on methacholine challenge (both p<0.05).¹⁸² Further clinical studies on Petasites and its effects on patients with asthma are warranted.

Hands-On and Mind-Body Medicine's Contribution to Asthma Treatment


Acupuncture

A number of studies have been conducted on the effect of acupuncture on asthma symptoms. Unfortunately, many suffer from poor methodology and/or poor data reporting, making it difficult to draw accurate conclusions regarding the therapeutic efficacy of acupuncture in asthma. Another challenge in acupuncture studies is the use of “sham” acupuncture or placebo acupuncture performed by non-acupuncturists. While these methodological flaws do exist, the overall trend in acupuncture research indicates that acupuncture can be a beneficial adjunctive therapy in the treatment of asthma.¹⁸³⁻¹⁸⁷ Jobst provides an excellent analysis of this issue.¹⁸⁸

Non-Acupuncture Injection Therapy – The Infraspinus Reflex

Harry Philibert, MD, of Metairie, Louisiana, has pioneered a non-acupuncture technique involving injection of a small amount of a saline-lidocaine solution into the infraspinus muscle bilaterally. Dr Philibert uses this technique on all asthma patients and

Figure 3: Infraspinatus Reflex Injection Technique.



claims an astounding “total remission” rate of 84 percent. He began using this technique because he found the majority of asthma patients had extremely painful infraspinatus muscles to palpation. Upon injecting these tender points with a saline-lidocaine-hydrocortisone solution (2 mL of a 25 mg/mL hydrocortisone acetate solution added to a 50 mL bottle of 0.5% lidocaine HCl – inject 0.5 mL into belly of infraspinatus and 0.5 mL into the infrascapular fossa bilaterally) he found the tender points resolved, and in those patients with asthma, so did their asthma symptoms.¹⁸⁹⁻¹⁹¹ This technique is simple and usually involves one set of injections (Figure 3). Dr. Philibert now uses only the lidocaine-saline solution.¹⁹²

Biofeedback

Biofeedback training appears to be a helpful adjunct in asthma treatment protocols. Biofeedback emphasizing relaxation and/or

beneficial slow, deep, diaphragmatic breathing was noted to decrease symptom severity, decrease medication usage, decrease emergency room visits, and increase lung function values.^{193,194} Transcendental meditation training yielded similar results.¹⁹⁵

Yoga Breathing

Yoga, which has a strong emphasis on breathing techniques, has been demonstrated to benefit asthma patients. Yoga training programs enrolling a total of 715 patients demonstrated significant improvement in asthma symptoms, medication usage, peak flow rate, and exercise tolerance.¹⁹⁶⁻¹⁹⁹ It appears the breathing techniques utilized are responsible for the beneficial effects seen in asthma, not the

yoga postures alone.

Massage

Asthma patients can also benefit from regular massage therapy. Massage relaxes the musculature and reduces anxiety. A study of children with asthma who received massage daily for 30 days demonstrated increased peak airflow and FEV1 during the course of the study.²⁰⁰

Chiropractic/Osteopathic Manipulation

Many osteopathic and chiropractic physicians perform spinal adjustments on patients with asthma, and symptomatic improvements are often noted.²⁰¹ This is an area that needs further well-designed trials to ascertain whether symptomatic or lasting benefit is derived from this type of therapy. Studies to date

have not confirmed objective benefit from the use of manual manipulation in asthma.²⁰²⁻²⁰⁴ While spinal adjustments certainly can help an individual breathe better if there is a structural and neurological element making it difficult to breathe, they cannot be expected to alter the underlying immunological and biochemical dysfunctions of the asthmatic.

Conclusions

Asthma is at best an annoying condition, and at worst a debilitating, even deadly disease. Research in the last decade has offered significant insight into the pathophysiology of asthma; however, there is still much unknown about the prevention, pathophysiology, and treatment of this increasingly prevalent disease. Many studies of single nutrient or botanical approaches to asthma treatment have yielded subjective improvements only, or even contradictory results. Since asthma is a multi-factorial health problem, it is not surprising that single therapies often work in some patients, but not others. To obtain a true representation of the usefulness of natural therapies in asthma, researchers need to study multiple interventions. This can still be done in a controlled manner that can produce meaningful data.

The incidence of asthma, especially in children, is escalating at an alarming rate – more than 100 percent over the last 20 years. There are now over 17 million individuals in the United States suffering with asthma – 5,000 of them will die from asthma this year. The genetic component of atopy remains the strongest risk factor for the incidence of asthma. But human genetics have not changed that much in the last 20 years. Therefore, there must be a multi-factorial process that is triggering a genetic predisposition, or causing many new, non-heritable cases of asthma.

New, more airtight home construction, indoor and outdoor environmental pollutants, nutritional deficiencies, viral and fungal

infections, gastroesophageal reflux, and vaccinations have each been implicated in the rising incidence of asthma.

Inflammation and airway hyper-reactivity are at the core of asthma pathophysiology, with an out-of-balance immune process at the center of both problems. The immune system in asthmatic individuals tends to have an overabundance of CD4⁺ Th2 cellular activity, resulting in production of cytokines that promote and enhance the inflammatory cascade. Numerous nutritional, environmental, and immunological insults also push the immune system toward Th2 activity, including viral and chlamydial infection, tobacco smoke, heavy metal toxicity, and zinc deficiency.

Conventional asthma treatment is currently aimed at inflammation (inhaled steroids are the mainstay of treatment) and airway hyper-responsiveness (short-acting bronchodilators are often used here). The use of new anti-leukotriene drugs is also increasing.

Natural approaches toward the treatment of asthma overlap conventional treatment in a few areas. First, it is essential for asthma patients to monitor their lung function daily with a peak flow meter. They are relatively inexpensive, and can give the individual an objective measurement of how the treatment is working. Another essential component is a symptom diary, which enables the patient to monitor how different treatments and dosage regimens are working, as well as providing insight into potential food or environmental triggers. Efforts to improve the patient's home and working environment are also important, especially in toxicity or allergy-related asthma. Maintaining a clean bedroom space is essential. HEPA filters and mattress and pillow covers can also be helpful.

There are several natural treatments that can have an impact on the immune imbalance in asthma. Plant sterols and sterolins are a promising treatment, as they have a rebalancing effect on Th1:Th2 ratios. More clinical studies are needed, and are currently

underway. Zinc deficiency can cause an improper Th1:Th2 ratio, and studies suggest proper zinc intake may affect this immune imbalance positively.

It is also important to address the anti-oxidant/oxidant balance in the body. Since inflammation promotes the formation of reactive oxygen species, and asthmatics have an increased oxidant burden, nutrients such as vitamins C and E, zinc, and selenium are important to consider. Symptomatic improvement was seen after selenium supplementation – even though a small amount was used (46 mcg/day). The vitamin C literature does not provide an unequivocal answer regarding its use; however, the negative studies seem to be looking for an immediate response to supplementation. The positive studies showed increases in lung function with long-term increases in vitamin C intake.

Intracellular magnesium is lower in asthma patients, and it is essential to supplement these individuals with magnesium. The magnesium literature is also fraught with contradictory information regarding intravenous use for severe asthma attacks. But the bottom line is – these people are deficient. Vitamins B6 and B12 may also be helpful, as the literature and anecdotal reports suggest they are both deficient in some asthma patients and supplementation lessens asthma symptomatology.

Other natural therapies seek to address the inflammatory problem. Quercetin reduces histamine degranulation and the subsequent release of histamine and inflammatory leukotrienes. To date, *Boswellia* is the only known specific 5-lipoxygenase inhibitor in the plant kingdom, and has been shown to decrease asthma symptomatology, both subjectively and objectively. Butterbur extract might have a similar mode of action, but more clinical information would be helpful for the asthma patient. The mechanism of action of *Tylophora* is unknown, but clinically it can provide a great deal of relief to the asthmatic. Relatively long

lasting symptomatic and objective relief was shown with short-term dosing in two clinical studies.

Omega-3 fatty acids should be included in the diet or supplemented on a long-term basis. It is unknown why some fish oil studies are positive and some are negative, as they are proven to lower 4-series leukotrienes. Possibly these oils need to be consumed over a longer period than these studies allowed, and perhaps more attention needs to be paid to the overall fatty acid ratio in the diet, as well as supplementing with omega-3 oils. Long-term epidemiological studies show lower incidence of inflammatory conditions, including asthma, with increased fish intake.

Addressing toxicity may also be an important factor. Yeast/fungi in the patient's environment can be a potent allergen. Intestinal yeast overgrowth after antibiotic treatment, which can be a common occurrence in the asthma patient, is another consideration. Heavy metals increase the toxic burden and should be investigated.

Physical medicine modalities appear to be an effective adjunct to the other therapies mentioned above. Massage, biofeedback, acupuncture, yoga, and spinal manipulation all have shown symptomatic – and in some cases objective – improvement.

Treating the asthma patient can be a most difficult and frustrating endeavor. However, non-invasive environmental modifications, dietary suggestions, and supplements can help reduce the overall immunological and biochemical burden on the individual with asthma. In some cases, they can prevent the patient from having to use beta-agonist bronchodilators or steroids, or they can be used as an adjunct to these allopathic medications, to allow less usage or lower dosing. However they are used, it is imperative for the practitioner to investigate the patient's reactivity to substances in their environment and promote avoidance of those substances, as well as encouraging proper nutrition and

lifestyle characteristics that will reduce the overall toxic burden of these individuals.

I would like to thank my daughter Sophie (who has asthma) for teaching me an extraordinary amount about this disease, and for allowing me to see first-hand what this disease is about from a very personal perspective.

References

1. Stores G, Ellis AJ, Wiggs L, et al. Sleep and psychological disturbance in nocturnal asthma. *Arch Dis Child* 1998;78:413-419.
2. Aubier M. Air pollution in allergic asthma. *Rev Mal Respir* 2000;17:159-165. [Article in French]
3. Li XY, Gilmour PS, Donaldson K, MacNee W. In vivo and in vitro proinflammatory effects of particulate air pollution (PM10). *Environ Health Perspect* 1997;105:S1279-S1283.
4. Bjorksten B. Epidemiology of pollution-induced airway disease in Scandinavia and Eastern Europe. *Allergy* 1997;52:S23-S25.
5. Parronchi P, Brugnolo F, Sampognaro S, Maggi E. Genetic and environmental factors contributing to the onset of allergic disorders. *Int Arch Allergy Immunol* 2000;121:2-9.
6. Kemp T, Pearce N, Fitharris P, et al. Is infant immunization a risk factor for childhood asthma or allergy? *Epidemiology* 1997;8:678-680.
7. Odent MR, Culpin EE, Kimmel T. Pertussis vaccination and asthma: is there a link? *JAMA* 1994;272:592-593.
8. Nilsson L, Kjellman NIM, Storsaeter J, et al. Lack of association between pertussis vaccination and symptoms of asthma and allergy. *JAMA* 1996;275:760.
9. Erb KJ, Le Gros G. The role of Th2 type CD4+ T cells and Th2 type CD8+ T cells in asthma. *Immunol Cell Biol* 1996;74:206-208
10. Kon OM, Kay AB. T cells and chronic asthma. *Int Arch Allergy Immunol* 1999;118:133-135.
11. Selgrade MK, Lawrence DA, Ullrich SE, et al. Modulation of T-helper cell populations: potential mechanisms of respiratory hypersensitivity and immune suppression. *Toxicol Appl Pharmacol* 1997;145:218-229.
12. Kline JN, Hunninghake GW. T-lymphocyte dysregulation in asthma. *Proc Soc Exp Biol Med* 1994;207:243-253.
13. Umetsu DT, DeKruyff RH. Th1 and Th2 CD4+ cells in the pathogenesis of allergic diseases. *Proc Soc Exp Biol Med* 1997;215:11-20.
14. Ray A, Cohn L. Th2 cells and GATA-3 in asthma: new insights into the regulation of airway inflammation. *J Clin Invest* 1999;104:985-993.
15. Bodey KJ, Semper AE, Redington AE, et al. Cytokine profiles of BAL T cells and T-cell clones obtained from human asthmatic airways after local allergen challenge. *Allergy* 1999;54:1083-1093.
16. Le Gros G, Erb K, Harris N, et al. Immunoregulatory networks in asthma. *Clin Exp Allergy* 1998;28:S92-S96.
17. Bell SJ, Metzger WJ, Welch CA, Gilmour MI. A role for Th2 T-memory cells in early airway obstruction. *Cell Immunol* 1996;170:185-194.
18. Coyle AJ, Bertrand C, Tsuyuki S, et al. IL-4 differentiates naive CD8+ T cells to a "Th2-like" phenotype: a link between viral infections and bronchial asthma. *Ann N Y Acad Sci* 1996;796:97-103.
19. Anonymous. Treating asthma and rhinitis as one disease. *Clinician Rev* 2000;10:185.
20. Jarikre LN, Ogisi FO. Nasal symptoms in bronchial asthma. *East Afr Med J* 1990;67:9-12.
21. Peat JK, Tovey E, Toelle BG, et al. House-dust mite allergens: a major risk factor for childhood asthma in Australia. *Am J Respir Crit Care Med* 1996;153:141-146.
22. Sporik R, Holgate ST, Platts-Mills TAE, Cogswell JJ. Exposure to house-dust mite allergen (Der p 1) and the development of asthma in childhood. A prospective study. *N Engl J Med* 1990;323:502-507.
23. Sears MR, Herbison GP, Holdaway MD, et al. The relative risks of sensitivity to grass pollen, house dust mite and cat dander in the development of childhood asthma. *Clin Exp Allergy* 1989;19:419-424.
24. Platts-Mills TA, Thomas WR, Aalberse RC, et al. Dust mite allergens and asthma: report of a second international workshop. *J Allergy Clin Immunol* 1992;89:1046-1060.

25. Bjornsson E, Norback D, Janson C, et al. Asthmatic symptoms and indoor levels of micro-organisms and house dust mites. *Clin Exp Allergy* 1995;25:423-431.
26. Call RS, Smith TF, Morris E, et al. Risk factors for asthma in inner city children. *J Pediatr* 1992;121:862-866.
27. Wan H, Winton H, Soeller C, et al. Der p 1 facilitates transepithelial allergen delivery by disruption of tight junctions. *J Clin Invest* 1999;104:123-133.
28. Popplewell EJ, Innes VA, Lloyd-Hughes S, et al. The effect of high-efficiency and standard vacuum-cleaners on mite, cat and dog allergen levels and clinical progress. *Pediatr Allergy Immunol* 2000;11:142-148.
29. Rosenstreich DL, Eggleston P, Kattan M, et al. The role of cockroach allergy and exposure to cockroach allergen in causing morbidity among inner-city children with asthma. *N Engl J Med* 1997;336:1356-1363.
30. Plaschke P, Janson C, Balder B, et al. Adult asthmatics sensitized to cats and dogs: symptoms, severity, and bronchial hyperresponsiveness in patients with furred animals at home and patients without these animals. *Allergy* 1999;54:843-850.
31. Jones AP. Asthma and the home environment. *J Asthma* 2000;37:103-124.
32. Hong CY, et al. Life-style and behavioral risk factors associated with asthma morbidity in adults. *QJM* 1994;87:639-645.
33. Sunyer J, Soriano J, Anto JM, et al. Sensitization to individual allergens as risk factors for lower FEV1 in young adults. European Community Respiratory Health Survey. *Int J Epidemiol* 2000;29:125-130.
34. Roost HP, Kunzli N, Schindler C, et al. Role of current and childhood exposure to cat and atopic sensitization. European Community Respiratory Health Survey. *J Allergy Clin Immunol* 1999;104:941-947.
35. Ichikawa K, Iwasaki E, Baba M, Chapman MD. High prevalence of sensitization to cat allergen among Japanese children with asthma, living without cats. *Clin Exp Allergy* 1999;29:754-761.
36. Platts-Mills TA, Sporik R, Ingram JM, Honsinger R. Dog and cat allergens and asthma among school children in Los Alamos, New Mexico, USA; altitude 7,200 feet. *Int Arch Allergy Immunol* 1995;107:301-303.
37. Lonnkvist K, Hallden G, Dahlen SE, et al. Markers of inflammation and bronchial reactivity in children with asthma, exposed to animal dander in school dust. *Pediatr Allergy Immunol* 1999;10:45-52.
38. Perzanowski MS, Ronmark E, Nold B, et al. Relevance of allergens from cats and dogs to asthma in the northernmost province of Sweden: schools as a major site of exposure. *J Allergy Clin Immunol* 1999;103:1018-1024.
39. Custovic A, Fletcher A, Pickering CA, et al. Domestic allergens in public places III: house dust mite, cat, dog and cockroach allergens in British hospitals. *Clin Exp Allergy* 1998;28:53-59.
40. Hodson T, Custovic A, Simpson A, et al. Washing the dog reduces dog allergen levels, but the dog needs to be washed twice a week. *J Allergy Clin Immunol* 1999;103:581-585.
41. Green R, Simpson A, Custovic A, et al. The effect of air filtration on airborne dog allergen. *Allergy* 1999;54:484-488.
42. Onorato J, Merland N, Terral C, et al. Placebo-controlled double-blind food challenge in asthma. *J Allergy Clin Immunol* 1986;78:1139-1146.
43. Yazicioglu M, Baspinar I, Ones U, et al. Egg and milk allergy in asthmatic children: assessment by immulite allergy food panel, skin prick tests and double-blind placebo-controlled food challenges. *Allergol Immunopathol* 1999;27:287-293.
44. Nekom KL. Nutritional triggers in asthma. *Acta Microbiol Immunol Hung* 1998;45:113-117.
45. Woods RK, Weiner J, Abramson M, et al. Patients' perceptions of food-induced asthma. *Aust NZ J Med* 1996;26:504-512.
46. Baker JC, Duncanson RC, Tunnicliffe WS, Ayres JG. Development of a standardized methodology for double-blind, placebo-controlled food challenge in patients with brittle asthma and perceived food intolerance. *J Am Diet Assoc* 2000;100:1361-1367.
47. Caffarelli C, Deriu FM, Terzi V, et al. Gastrointestinal symptoms in patients with asthma. *Arch Dis Child* 2000;82:131-135.
48. Benard A, Desreumeaux P, Huglo D, et al. Clinical aspects of allergic disease. Increased intestinal permeability in bronchial asthma. *J Allergy Clin Immunol* 1996;97:1173-1178.

49. Gumowski P, Leah B, Chaves I, Girard JP. Chronic asthma and rhinitis due to *Candida albicans*, epidermophyton, and trichophyton. *Ann Allergy* 1987;59:48-51.
50. Obtulowicz K, Pawlik B, Gluszko P. Mycoflora in bronchial asthma. *Allerg Immunol* 1981;27:28-34.
51. Douwes J, Zuidhof A, Doekes G, et al. (1±3) beta-D-glucan and endotoxin in house dust and peak flow variability in children. *Am J Respir Crit Care Med* 2000;162:1348-1354.
52. Black PN, Udy AA, Brodie SM. Sensitivity to fungal allergens is a risk factor for life-threatening asthma. *Allergy* 2000;55:501-504.
53. Arzumanyan VG, Magarshak OO, Semenov BF. Yeast fungi in patients with allergic diseases: species variety and sensitivity to antifungal drugs. *Bull Exp Biol Med* 2000;129:704-708.
54. Akiyama K. The role of fungal allergy in bronchial asthma. *Nippon Ishinkin Gakkai Zasshi* 2000;41:149-155. [article in Japanese]
55. Savolainen J, Viander M, Koivikko A. IgE-, IgA-, and IgG-antibody responses to carbohydrate and protein antigens of *Candida albicans* in asthmatic children. *Allergy* 1990;45:54-63.
56. d'Ostiani CF, Del Sero G, Bacci A, et al. Dendritic cells discriminate between yeasts and hyphae of the fungus *Candida albicans*. Implications for initiation of T helper cell immunity in vitro and in vivo. *J Exp Med* 2000;191:1661-1674.
57. Romani L. Immunity to *Candida albicans*: Th1, Th2 cells and beyond. *Curr Opin Microbiol* 1999;2:363-367.
58. Pucetti P, Romani L, Bistoni F. A TH1-TH2-like switch in candidiasis: new perspectives for therapy. *Trends Microbiol* 1995;3:237-240.
59. Romani L, Mencacci A, Tonnetti L, et al. IL-12 is both required and prognostic in vivo for T helper type 1 differentiation in murine candidiasis. *J Immunol* 1994;153:5167-5175.
60. Cenci E, Romani L, Mencacci A, et al. Interleuin-4 and interleukin-10 inhibit nitric oxide-dependent macrophage killing of *Candida albicans*. *Eur J Immunol* 1993;23:1034-1038.
61. Kimura G, Ogurusu K, Soda R, et al. Studies on INF-gamma production by peripheral blood mononuclear cells cultured with *Candida* antigen in asthmatics. *Aerugi* 1992;41:1717-1721. [article in Japanese]
62. Tanizaki Y, Kitani H, Okazaki M, et al. Humoral and cellular immunity to *Candida albicans* in patients with bronchial asthma. *Intern Med* 1992;31:766-769.
63. Marin J, Jeler-Kacar D, Levstek V, Macek V. Persistence of viruses in upper respiratory tract of children with asthma. *J Infect* 2000;41:69-72.
64. Hahn DL. Chlamydia pneumoniae, asthma, and COPD: what is the evidence? *Ann Allergy Asthma Immunol* 1999;83:271-288.
65. Mills GD, Lindeman JA, Fawcett JP, et al. Chlamydia pneumoniae serological status is not associated with asthma in children or young adults. *Int J Epidemiol* 2000;29:280-284.
66. Black PN, Scicchitano R, Jenkins CR, et al. Serological evidence of infection with Chlamydia pneumoniae is related to the severity of asthma. *Eur Respir J* 2000;15:254-259.
67. Kneyber MCJ, Steyerberg EW, de Groot R, Moll HA. Long-term effects of respiratory syncytial virus (RSV) bronchiolitis in infants and young children: a quantitative review. *Acta Paediatr* 2000;89:654-660.
68. Stein RT, Sherrill D, Morgan WJ, et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. *Lancet* 2000;354:541-545.
69. Graham BS, Johnson TR, Peebles RS. Immune-mediated disease pathogenesis in respiratory syncytial virus infection. *Immunopharmacology* 2000;48:237-247.
70. Bendelja K, Gagro A, Bace A, et al. Predominant type-2 response in infants with respiratory syncytial virus (RSV) infection demonstrated by cytokine flow cytometry. *Clin Exp Immunol* 2000;121:332-338.
71. Seymour BWP, Pinkerton KE, Friebershauser KE, et al. Second-hand smoke is an adjuvant for T helper-2 responses in a murine model of allergy. *J Immunol* 1997;159:6169-6175.
72. Gorrie MJ, Quasim FJ, Whittle CJ, et al. Exogenous type-1 cytokines modulate mercury-induced hyper-IgE in the rat. *Clin Exp Immunol* 2000;121:17-22.
73. Field SK, Evans JA, Price LM. The effects of acid perfusion of the esophagus on ventilation and respiratory sensation. *Am J Respir Crit Care Med* 1998;157:1058-1062.

74. Sontag S. Why do the published data fail to clarify the relationship between gastroesophageal reflux and asthma? *Am J Med* 2000;108:159S-169S.
75. Chakrabarti S, Singh K, Singh V, et al. Airway response to acid instillation in esophagus in bronchial asthma. *Indian J Gastroenterol* 1995;14:44-47.
76. Mansfield LE, Stein MR. Gastroesophageal reflux and asthma; a possible reflex mechanism. *Ann Allergy* 1978;41:224-226.
77. Schan CA, Harding SM, Haile JM, et al. Gastroesophageal reflux-induced bronchoconstriction. An intraesophageal acid infusion study using state-of-the-art technology. *Chest* 1994;106:731-737.
78. Davis RS, Larsen GL, Grunstein MM. Respiratory response to intraesophageal acid infusion in asthmatic children during sleep. *J Allergy Clin Immunol* 1983;72:393-398.
79. Richter JE. Gastroesophageal reflux disease and asthma: the two are directly related. *Am J Med* 2000;108:153S-158S.
80. Chakrabarti S, Singh K, Singh V, et al. Airway response to acid instillation in esophagus in bronchial asthma. *Indian J Gastroenterol* 1995;14:44-47.
81. Harding SM, Guzzo MR, Maples RV, et al. Gastroesophageal reflux induced bronchoconstriction: vagolytic doses of atropine diminish airway responses to esophageal acid infusion. *Am J Respir Crit Care Med* 1995;151A589. Abstract.
82. Lodi U, Harding SM, Coghlan HC, et al. Autonomic regulation in asthmatics with gastroesophageal reflux. *Chest* 1997;111:65-70.
83. Tuchman DN, Boyle JT, Pack AI, et al. Comparison of airway responses following tracheal or esophageal acidification in the cat. *Gastroenterology* 1984;87:872-881.
84. Ruth M, Carlsson S, Mansson I, et al. Scintigraphic detection of gastro-pulmonary aspiration in patients with respiratory disorders. *Clin Physiol* 1993;13:19-33.
85. Chernow B, Johnson LF, Janowitz WR, Castell DO. Pulmonary aspiration as a consequence of gastroesophageal reflux: a diagnostic approach. *Dig Dis Sci* 1979;24:839-844.
86. Singh V, Jain NK. Asthma as a cause for, rather than a result of, gastroesophageal reflux. *J Asthma* 1983;20:241-243.
87. Wright JV. Treatment of childhood asthma with parenteral vitamin B12, gastric re-acidification, and attention to food allergy, magnesium, and pyridoxine. Three case reports with background and an integrated hypothesis. *J Nutr Med* 1990;1:277-282.
88. Kelly GS. Hydrochloric acid: physiological functions and clinical implications. *Altern Med Rev* 1997;2:116-127.
89. Anderson SD, Holzer K. Exercise-induced asthma: is it the right diagnosis in elite athletes? *J Allergy Clin Immunol* 2000;106:419-428.
90. Freed AN. Models and mechanisms of exercise-induced asthma. *Eur Respir J* 1995;8:1770-1785.
91. Brusasco V, Crimi E. Allergy and sports: exercise-induced asthma. *Int J Sports Med* 1994;15:S184-186.
92. Potter PC, Klein M, Weinberg EG. Hydration in severe acute asthma. *Arch Dis Child* 1991;66:216-219.
93. Anderson SD. Is there a unifying hypothesis for exercise-induced asthma? *J Allergy Clin Immunol* 1984;73:660-665.
94. Vally H, deKlerk N, Thompson PJ. Alcoholic drinks: important triggers for asthma. *J Allergy Clin Immunol* 2000;105:462-467.
95. Centanni S, Di Marco F, Castagna F, et al. Psychological issues in the treatment of asthmatic patients. *Respir Med* 2000;94:742-749.
96. Mancuso CA, Peterson MG, Charlson ME. Effects of depressive symptoms on health-related quality of life in asthma patients. *J Gen Intern Med* 2000;15:301-310.
97. Ritz T, Steptoe A, DeWilde S, Costa M. Emotions and stress increase respiratory resistance in asthma. *Psychosom Med* 2000;62:401-412.
98. Smyth JM, Soefer MH, Hurewitz A, et al. Daily psychosocial factors predict levels and diurnal cycles of asthma symptomatology and peak flow. *J Behav Med* 1999;22:179-193.
99. Miller BD, Wood BL. Psychophysiological reactivity in asthmatic children: a cholinergically mediated confluence of pathways. *J Am Acad Child Adolesc Psychiatry* 1994;33:1236-1245.
100. Doelman CJA, Bast A. Oxygen radicals in lung pathology. *Free Radical Biol Med* 1990;9:381-400.

101. Cluzel M, Damon M, Chanez P, et al. Enhanced alveolar cell luminol-dependent chemiluminescence in asthma. *J Allergy Clin Immunol* 1987;80:195-201.
102. Calhoun WJ, Salisbury SM, Bush RK, Busse WW. Increased superoxide release from alveolar macrophages in symptomatic asthma. *Am Rev Respir Dis* 1987;135:A224.
103. Kelly FJ, Mudway I, Blomberg A. Altered lung antioxidant status in patients with mild asthma. *Lancet* 1999;354:482-483.
104. Kalayci O, Besler T, Kilinc K, et al. Serum levels of antioxidant vitamins (alpha tocopherol, beta carotene, and ascorbic acid) in children with bronchial asthma. *Turk J Pediatr* 2000;42:17-21.
105. Schwartz J, Weiss ST. Relationship between dietary vitamin C intake and pulmonary function in the first national health and nutrition examination survey (NHANES 1). *Am J Clin Nutr* 1994;59:110-114.
106. Britton JR, Pavord ID, Richards KA, et al. Dietary antioxidants and lung function in the general population. *Am J Resp Crit Care Med* 1995;151:1383-1387.
107. Dow L, Tracey M, Villar A, et al. Does dietary intake of vitamins C and E influence lung function in older people? *Am J Resp Crit Care Med* 1996;154:1401-1404.
108. Ness AR, Khaw KT, Bingham D, Day NE. Vitamin C status and respiratory function. *Eur J Clin Nutr* 1996;50:573-579.
109. Mohsenin V, Dubois AR, Douglas JS. Effect of ascorbic acid on response to methacholine challenge in asthmatic subjects. *Am Rev Respir Dis* 1983;127:143-147.
110. Malo J, Cartier A, Pineau L, et al. Lack of acute effects of ascorbic acid on spirometry and airway responsiveness to histamine in subjects with asthma. *J Allergy Clin Immunol* 1986;78:1153-1158.
111. Schachter AN, Schlesinger A. The attenuation of exercise-induced bronchospasm by ascorbic acid. *Ann Allergy* 1982;49:146-151.
112. Monteleone CA, Sherman AR. Nutrition and asthma. *Arch Intern Med* 1997;157:23-34.
113. Bielory L, Gandhi R. Asthma and vitamin C. *Ann Allergy* 1994;73:89-96.
114. Reynolds RD, Natta CL. Depressed plasma pyridoxal phosphate concentrations in adult asthmatics. *Am J Clin Nutr* 1985;41:684-688.
115. Collipp PJ, Goldzier S, Weiss N, et al. Pyridoxine treatment of childhood bronchial asthma. *Ann Allergy* 1975;35:93-97.
116. Sur S, Camara M, Buchmeier A, et al. Double-blind trial of pyridoxine (vitamin B6) in the treatment of steroid-dependent asthma. *Ann Allergy* 1993;70:147-152.
117. Shimizu T, Maeda S, Mochizuki H, et al. Theophylline attenuates circulating vitamin B6 levels in children with asthma. *Pharmacology* 1994;49:392-397.
118. Shimizu T, Maeda S, Arawaka H, et al. Relation between theophylline and circulating vitamin levels in children with asthma. *Pharmacology* 1996;53:384-389.
119. Wright JV, Gaby AR. Major nutrients: a brief review. Wright-Gaby Nutrition Institute 1994.
120. Alamoudi OS. Hypomagnesemia in chronic, stable asthmatics: prevalence, correlation with severity and hospitalization. *Eur Respir J* 2000;16:427-431.
121. Hashimoto Y, Nishimura Y, Maeda H, Yokoyama M. Assessment of magnesium status in patients with bronchial asthma. *J Asthma* 2000;37:489-496.
122. Dominguez LJ, Barbagallo M, Di Lorenzo G, et al. Bronchial reactivity and intracellular magnesium: a possible mechanism for the bronchodilating effect of magnesium in asthma. *Clin Sci* 1998;95:137-142.
123. Landon RA, Young EA. Role of magnesium in regulation of lung function. *J Am Diet Assoc* 1993;93:674-677.
124. Britton J, Pavord I, Richards K, et al. Dietary magnesium, lung function, wheezing, and airway hyperreactivity in a random adult population sample. *Lancet* 1994;344:357-362.
125. Hill J, Micklewright A, Lewis S, Britton J. Investigation of the effect of short-term change in dietary magnesium intake in asthma. *Eur Respir J* 1997;10:2225-2229.
126. Harari M, Barzillai R, Shani J. Magnesium in the management of asthma: critical review of acute and chronic treatments, and Deutsches Medizinisches Zentrum's (DMZ's) clinical experience at the dead sea. *J Asthma* 1998;35:525-536.
127. Schiermeyer RP, Finkelstein JA. Rapid infusion of magnesium sulfate obviates need for intubation in status asthmaticus. *Am J Emerg Med* 1993;12:164-166.

128. McNamara RM, Spivey WH, Skobeloff E, Jacobowitz S. Intravenous magnesium sulfate in the management of acute respiratory failure complicating asthma. *Ann Emerg Med* 1989;18:197-199.
129. Gurkan F, Haspolat K, Bosnak M, et al. Intravenous magnesium sulphate in the management of moderate to severe acute asthmatic children nonresponding to conventional therapy. *Eur J Emerg Med* 1999;6:201-205.
130. Devi PR, Kumar L, Singhi SC, et al. Intravenous magnesium sulfate in acute severe asthma not responding to conventional therapy. *Indian Pediatr* 1997;34:389-397.
131. Ciarello L, Brousseau D, Reinert S. Higher-dose intravenous magnesium therapy for children with moderate to severe acute asthma. *Arch Pediatr Adolesc Med* 2000;154:979-983.
132. Okayama H, Aikawa T, Okayama M, et al. Bronchodilating effect of intravenous magnesium sulfate in bronchial asthma. *JAMA* 1987;257:1076-1078.
133. Sharma SK, Bhargava A, Pande JN. Effect of parenteral magnesium sulfate on pulmonary function in bronchial asthma. *J Asthma* 1994;31:109-115.
134. Rolla G, Bucca C, Brussino L, Colagrande P. Effect of intravenous magnesium infusion on salbutamol-induced bronchodilatation in patients with asthma. *Magnes Res* 1994;7:129-133.
135. Tiffany BR, Berk WA, Todd IK, White SR. Magnesium bolus or infusion fails to improve expiratory flow in acute asthma exacerbations. *Chest* 1993;104:831-834.
136. Boonyavorakul C, Thakkinstian A, Charoenpan P. Intravenous magnesium sulfate in acute severe asthma. *Respirology* 2000;5:221-225.
137. Rowe BH, Bretzlaff JA, Bourdon C, et al. Intravenous magnesium sulfate treatment for acute asthma in the emergency department: a systematic review of the literature. *Ann Emerg Med* 2000;36:181-190.
138. Rodrigo G, Rodrigo C, Burschtin O. Efficacy of magnesium sulfate in acute adult asthma: a meta-analysis of randomized trials. *Am J Emerg Med* 2000;18:216-221.
139. Kadrabova J, Mad'aric A, Podivinsky F, et al. Plasma zinc, copper and copper/zinc ratio in intrinsic asthma. *J Trace Elem Med Biol* 1996;10:50-53.
140. El-Kholy MS, Gas Allah MA, el-Shimi S, et al. Zinc and copper status in children with bronchial asthma and atopic dermatitis. *J Egypt Public Health Assoc* 1990;65:657-668.
141. Di Toro R, Galdo Capotorti G, Gialanella G, et al. Zinc and copper status of allergic children. *Acta Pediatr Scand* 1987;76:612-617.
142. Sprietsma JE. Modern diets and diseases: NO-zinc balance. *Med Hypotheses* 1999;53:6-16.
143. Sprietsma JE. Zinc-controlled Th1/Th2 switch significantly determines development of diseases. *Med Hypotheses* 1997;49:1-14.
144. Prasad AS. Zinc and immunity. *Mol Cell Biochem* 1998;188:63-69.
145. Beck FW, Prasad AS, Kaplan J, et al. Changes in cytokine production and T cell subpopulations in experimentally induced zinc-deficient humans. *Am J Physiol* 1997;272:E1002-1007.
146. Prasad AS, Beck FW, Grabowski SM, et al. Zinc deficiency: changes in cytokine production and T-cell subpopulations in patients with head and neck cancer and in noncancer subjects. *Proc Assoc Am Physicians* 1997;109:68-77.
147. Kadrabova J, Mad'aric A, Kovacicova Z, et al. Selenium status is decreased in patients with intrinsic asthma. *Biol Trace Elem Res* 1996;52:241-248.
148. Misso NLA, Powers KA, Gillon RL, et al. Reduced platelet glutathione peroxidase activity and serum selenium concentration in atopic asthmatic patients. *Clin Exp Allergy* 1996;26:838-847.
149. Flatt A, Pearce N, Thomson C, et al. Reduced selenium in asthmatic subjects in New Zealand. *Thorax* 1990;45:95-99.
150. Powell CVE, Nash AA, Powers HJ, Primhak RA. Antioxidant status in asthma. *Ped Pulmonology* 1994;18:34-38.
151. Hasselmark L, Malmgren R, Zetterstrom O, Unge G. Selenium supplementation in intrinsic asthma. *Allergy* 1993;48:30-36.
152. Lane SJ. Leukotriene antagonism in asthma and rhinitis. *Resp Med* 1998;92:795-809.
153. Busse WW, McGill KA, Horowitz RJ. Leukotriene pathway inhibitors in asthma and chronic obstructive pulmonary disease. *Clin Exp Allergy* 1999;29:110-115.
154. Yoshida S, Amayasu H, Sakamoto H, et al. Cromolyn sodium prevents bronchoconstriction and urinary LTE4 excretion in aspirin-induced asthma. *Ann Allergy Asthma Immunol* 1998;80:171-176.

155. Arm JP, Thien FCK, Lee TH. Leukotrienes, fish-oil, and asthma. *Allergy Proc* 1994;15:129-134.
156. Ritter JM, Taylor GW. Fish oil in asthma. *Thorax* 1988;43:81-83.
157. Schwartz J, Weiss ST. The relationship of dietary fish intake to level of pulmonary function in the first National Health and Nutrition Survey (NHANES 1). *Eur Respir J* 1994;7:1821-1824.
158. Hodge L, Salmoe CM, Hughes JM, et al. Effect of dietary intake of omega-3 and omega-6 fatty acids on severity of asthma in children. *Eur Respir J* 1998;11:361-365.
159. Villani F, Comazzi R, DeMaria P, Galimberti M. Effect of dietary supplementation with polyunsaturated fatty acids on bronchial hyperreactivity in subjects with seasonal asthma. *Respiration* 1998;65:265-269.
160. Broughton KS, Johnson CS, Pace BK, et al. Reduced asthma symptoms with n-3 fatty acid ingestion are related to 5-series leukotriene production. *Am J Clin Nutr* 1997;65:1011-1017.
161. Arm JP, Horton CE, Mencia-Huerta JM, et al. Effect of dietary supplementation with fish oil lipids on mild asthma. *Thorax* 1988;43:84-92.
162. Gopalakrishnan C, Shankarakarayanan D, Nazimudeen SK, Kameswaran L. Effect of tylophorine, a major alkaloid of *Tylophora indica*, on immunopathological and inflammatory reactions. *Indian J Med Res* 1980;71:940-948.
163. Udupa AL, Udupa SL, Guruswamy MN. The possible site of anti-asthmatic action of *Tylophora asthmatica* on pituitary-adrenal axis in albino rats. *Planta Med* 1991;57:409-413.
164. Thiruvengadam KV, Haranath K, Sudarsan S, et al. *Tylophora indica* in bronchial asthma. A controlled comparison with a standard anti-asthmatic drug. *J Indian Med Assoc* 1978;71:172-176.
165. Shivpuri DN, Menon MPS, Prakash D. A crossover double-blind study on *Tylophora indica* in the treatment of asthma and allergic rhinitis. *J Allergy* 1969;43:145-150.
166. Ammon HP, Safayhi H, Mack T, Sabieraj J. Mechanism of anti-inflammatory actions of curcumin and boswellic acids. *J Ethnopharmacol* 1993;38:113-119.
167. Ammon HP, Mack T, Singh GB, Safayhi H. Inhibition of leukotriene B4 formation in rat peritoneal neutrophils by an ethanolic extract of the gum resin exudate of *Boswellia serrata*. *Planta Med* 1991;57:203-207.
168. Sharma ML, Khajuria A, Kaul A, et al. Effect of *salvia guggal* ex-*Boswellia serrata* on cellular and humoral immune responses and leucocyte migration. *Agents Actions* 1988;24:161-164.
169. Gupta I, Gupta V, Parihar A, et al. Effects of *Boswellia serrata* gum resin in patients with bronchial asthma: results of a double-blind, placebo-controlled, 6-week clinical study. *Eur J Med Res* 1998;3:511-514.
170. Mascolo N, Pinto A, Capasso F. Flavonoids, leucocyte migration, and eicosanoids. *J Pharm Pharmacol* 1988;40:293-295.
171. Pearce FL, Befus AD, Bienenstock J. Mucosal mast cells. III. Effect of quercetin and other flavonoids on antigen-induced histamine secretion from rat intestinal mast cells. *J Allergy Clin Immunol* 1984;73:819-823.
172. Middleton E Jr, Drzewiecki G. Flavonoid inhibition of human basophil histamine release stimulated by various agents. *Biochem Pharmacol* 1984;33:3333-3338.
173. Anonymous. Quercetin; monograph. *Altern Med Rev* 1998;3:140-143.
174. Bouic PJ, Estebeth S, Liebenberg RW, et al. Beta-sitosterol and beta-sitosterol glycoside stimulate human peripheral blood lymphocyte proliferation: implications for their use as an immunomodulatory vitamin combination. *Int J Immunopharmacol* 1996;18:693-700.
175. Myers L, Bouic PJ. Flow cytometric analysis of the TH1-TH2 shift in allergic individuals using Moducare[®] (sterols/sterolins). 26th Annual Congress of the Physiology Society of Southern Africa: 1998.
176. Bouic PJ. Immunomodulation in HIV/AIDS: the Tygerberg/Stellenbosch University experience. *AIDS Bull* 197;6:18-20.
177. Bouic PJ, Lamprecht JH. Plant sterols and sterolins: a review of their immune-modulating properties. *Altern Med Rev* 1999;4:170-177.
178. Grossman M, Schmidramsl H. An extract of *Petasites hybridus* is effective in the prophylaxis of migraine. *Int J Clin Pharmacol Ther* 2000;38:430-435.
179. Bickel D, Roder T, Bestmann HJ, Brune K. Identification and characterization of inhibitors of peptido-leukotriene synthesis from *Petasites hybridus*. *Planta Med* 1994;60:318-322.

180. Brune K, Bickel D, Peskar BA. Gastro-protective effects by extracts of *Petasites hybridus*: the role of inhibition of peptidoleukotriene synthesis. *Planta Med* 1993;59:494-496.
181. Ko WC, Lei CB, Lin YL, Chen CF. Relaxant effects of petasins in isolated guinea pig trachea and their structure-activity relationships. *Planta Med* 2000;66:650-652.
182. Ziolo G, Samochowicz L. Study on clinical properties and mechanisms of action of *Petasites* in bronchial asthma and chronic obstructive bronchitis. *Pharm Acta Helv* 1998;72:378-380.
183. Yu DY, Lee SP. Effect of acupuncture on bronchial asthma. *Clin Sci Mol Med* 1976;51:503-509.
184. Jinsheng H. Clinical observation on 25 cases of hormone dependent bronchial asthma treated by acupuncture. *J Trad Chinese Med* 1998;18:27-30.
185. Xiansheng L. Combined use of acupuncture and blood injection at the back-shu points for treatment of allergic asthma – a report of 80 cases. *J Trad Chinese Med* 1997;17:207-210.
186. Junqi Z. Immediate antiasthmatic effect of acupuncture in 192 cases of bronchial asthma. *J Trad Chinese Med* 1990;10:89-93.
187. Zunhui G, Jinda Z. Effects of acupuncture on immunoglobins in patients with asthma and rheumatoid arthritis. *J Trad Chinese Med* 1995;15:102-105.
188. Jobst KA. Acupuncture in asthma and pulmonary disease: an analysis of efficacy and safety. *J Altern Complementary Med* 1996;2:179-206.
189. Philibert H. Asthma: palpation and injections. *J Fam Pract* 1995;40:121-122. [letter]
190. Philibert H. Asthma, rheumatoid arthritis and the autoimmune system. Presented at the Great Lakes College of Clinical Medicine annual meeting. Pittsburgh, PA. September 1997.
191. Philibert H. Treating pain by specific injection therapy. The infraspinatus reflex. Presented at the American Academy of Environmental Medicine, 34th Annual Meeting. October 1999.
192. Philibert H. Personal communication. April 2000.
193. Kern-Buell CL, McGrady AV, Conran PB, Nelson LA. Asthma severity, psychophysiological indicators of arousal, and immune function in asthma patients undergoing biofeedback-assisted relaxation. *Appl Psychophysiol Biofeedback* 2000;25:79-91.
194. Peper E, Tibbetts V. Fifteen-month follow-up with asthmatics utilizing EMG/incentive spirometer feedback. *Biofeedback Self Regul* 1992;17:143-151.
195. Wilson AF, Honsberger R, Chiu JT, Novey HS. Transcendental meditation and asthma. *Respiration* 1975;32:74-80.
196. Jain SC, Talukdar B. Evaluation of yoga therapy programme for patients of bronchial asthma. *Singapore Med J* 1993;34:306-308.
197. Jain SC, Rai L, Valecha A, et al. Effect of yoga training on exercise tolerance in adolescents with childhood asthma. *J Asthma* 1991;28:437-442.
198. Nagendra HR, Nagarathna R. An integrated approach of yoga therapy for bronchial asthma: a 3-54-month prospective study. *J Asthma* 1986;23:123-137.
199. Nagarathna R, Nagendra HR. Yoga for bronchial asthma: a controlled study. *Br Med J (Clin Res Ed)* 1985;291:1077-1079.
200. Field T, Henteleff T, Hernandez-Reif M, et al. Children with asthma have improved pulmonary functions after massage therapy. *J Pediatr* 1998;132:854-858.
201. Paul FA, Buser BR. Osteopathic manipulative treatment applications for the emergency department patient. *J Am Osteopath Assoc* 1996;96:403-409.
202. Hondras MA, Linde K, Jones AP. Manual therapy for asthma. *Cochrane Database Syst Rev* 2000;CD001002.
203. Balon J, Aker PD, Crowther ER, et al. A comparison of active and simulated chiropractic manipulation as adjunctive treatment for childhood asthma. *N Engl J Med* 1998;339:1013-1020.
204. Nielsen NH, Bronfort G, Bendix T, et al. Chronic asthma and chiropractic spinal manipulation: a randomized clinical trial. *Clin Exp Allergy* 1995;25:80-88.